RELAPSED ACUTE MYELOID LEUKEMIA
Clinical trials for RELAPSED ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to boost leukemia treatment
Disease control Recruiting nowThis study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will be e…
Matched conditions: RELAPSED ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for relapsed AML: experimental combo trial opens
Disease control Recruiting nowThis early-phase trial tests whether adding the experimental drug imetelstat to standard chemotherapy (azacitidine, with or without venetoclax) is safe and effective for adults with relapsed or refractory acute myeloid leukemia (AML). About 36 participants will receive the combin…
Matched conditions: RELAPSED ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Douglas Tremblay • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for kids with relapsed leukemia: experimental drug combo enters safety trial
Disease control Recruiting nowThis study tests whether adding a new drug called revumenib to two standard chemotherapy drugs (azacitidine and venetoclax) is safe for children and young adults whose acute myeloid leukemia (AML) has not responded to treatment or has returned. About 24 participants will receive …
Matched conditions: RELAPSED ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…
Matched conditions: RELAPSED ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:10 UTC